Comparative Pharmacology
Head-to-head clinical analysis: NORINYL 1 80 21 DAY versus TRI LO LINYAH.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORINYL 1 80 21 DAY versus TRI LO LINYAH.
NORINYL 1+80 21-DAY vs TRI-LO-LINYAH
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (a progestin) and ethinyl estradiol (an estrogen). Inhibits ovulation by suppressing gonadotropin release (FSH and LH). Also increases cervical mucus viscosity and alters endometrial morphology.
Combination estrogen-progestin oral contraceptive: suppresses gonadotropins (FSH and LH) via negative feedback, inhibiting ovulation; increases cervical mucus viscosity, reducing sperm penetration; alters endometrial structure, impairing implantation.
One tablet orally once daily for 21 days, followed by 7 days of no active treatment.
One tablet orally once daily for 21 days, followed by 7 days of placebo. Each tablet contains 0.180 mg norgestimate and 0.025 mg ethinyl estradiol for days 1-7, 0.215 mg/0.025 mg for days 8-14, and 0.250 mg/0.025 mg for days 15-21.
None Documented
None Documented
Norethindrone: 8-11 hours; Mestranol: 12-24 hours (metabolized to ethinyl estradiol with half-life 20-27 hours). Steady-state after 5-7 days.
Terminal elimination half-life: 12-15 hours; allows once-daily dosing but requires dose adjustment in renal impairment.
Renal (40-60% as metabolites), fecal (20-30%)
Renal: ~60% as unchanged drug; fecal/biliary: ~40% as metabolites.
Category C
Category C
Oral Contraceptive
Oral Contraceptive